0 results available. Select is focused ,type to refine list, press Down to open the menu,
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and int...
The following section summarizes insights on Nektar Therapeutics's Asset Efficiency:
We've identified the following companies as similar to Nektar Therapeutics because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Asset Efficiency in the risk category include:
A ratio that measures the amount of cash flow that a company generates from its assets.
Asset efficiency is an efficiency ratio that measures the cash flows created from assets without being skewed by income measurements. The asset efficiency is defined as:
"Asset Efficiency = Cash From Operations / Average Assets",
Asset Efficiency for Nektar Therapeutics is calculated as follows:
Cash From Operations [ -175.7 M ]
(/) Average Total Assets over Period [ 350.9 M ]
(=) Asset Efficiency [ −50.1% ]
The tables below summarises Nektar Therapeutics’s asset efficiency over the last five years:
| Fiscal Year | Cash From Operations | Average Assets | Asset Efficiency |
|---|---|---|---|
| 2020-12-31 | -313.3 M | 1.758 B | −17.8% |
| 2021-12-31 | -412.7 M | 1.328 B | −31.1% |
| 2022-12-31 | -304 M | 913.9 M | −33.3% |
| 2023-12-31 | -192.6 M | 554.3 M | −34.7% |
| 2024-12-31 | -175.7 M | 350.9 M | −50.1% |
The tables below summarizes Nektar Therapeutics’s asset efficiency over the last four quarters:
| Quarter Ending | Cash From Operations | Average Assets | Asset Efficiency |
|---|---|---|---|
| 2024-03-31 | -47.888 M | NA | NA |
| 2024-06-30 | -37.702 M | NA | NA |
| 2024-09-30 | -43.932 M | NA | NA |
| 2024-12-31 | -46.187 M | 92.249 M | −50.1% |
The chart above depicts the distribution of asset efficiency for companies operating in the Healthcare sector in the Developed economic region. Over 2,390 companies were considered in this analysis, and 2,303 had meaningful values. The average asset efficiency of companies in the sector is -35.1% with a standard deviation of 58.7%.
Nektar Therapeutics's Asset Efficiency of -50.1% ranks in the 25.6% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 2,399 |
| Included Constituents | 2,303 |
| Min | -344.9% |
| Max | 28.2% |
| Median | -17.8% |
| Mean | -35.1% |
| Standard Deviation | 58.7% |
You can find companies with similar asset efficiency using this stock screener.